Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 2/2017

01-02-2017 | Original Article

A revisit to quantitative PET with 18F-FDOPA of high specific activity using a high-resolution condition in view of application to regenerative therapy

Authors: Go Akamatsu, Akihito Ohnishi, Kazuki Aita, Hiroyuki Nishida, Yasuhiko Ikari, Masahiro Sasaki, Nobuo Kohara, Michio Senda

Published in: Annals of Nuclear Medicine | Issue 2/2017

Login to get access

Abstract

Objective

With the advent of regenerative/cell therapy for Parkinson’s disease (PD), 18F-FDOPA has drawn new attention as a biomarker of the therapeutic that cannot be evaluated with radiopharmaceuticals for dopamine transporter. Since most previous 18F-FDOPA PET studies were carried out many years ago with a PET scanner of lower resolution and with 18F-FDOPA of low specific activity synthesized from 18F-F2, we used a newer PET/CT scanner with a high-resolution condition and 18F-FDOPA synthesized from 18F-F− to re-evaluate this technique on normal subjects and patients with PD, together with D2 receptor imaging with 11C-raclopride (RAC).

Methods

PET scans were carried out with 18F-FDOPA for 120 min and with 11C-RAC for 60 min on 10 patients clinically diagnosed with PD and on 10 normal control subjects. Image reconstruction parameters were optimized with phantom experiments. Graphical analysis and the ratio method for the late-phase images were performed to quantify the striatal uptakes.

Results

The specific activity of 18F-FDOPA was as high as 4000 MBq/nmol. We empirically determined appropriate reconstruction parameters to obtain high-resolution PET images with enough quantitative accuracy. Both 18F-FDOPA and 11C-RAC PET showed higher uptake values on normal subjects than those of the previous studies probably due to high-resolution. Quantified ratio values strongly correlated with the graphical values for both tracers. Furthermore, 18F-FDOPA uptake in the substantia nigra was clearly visualized in most subjects.

Conclusion

Quantitative 18F-FDOPA and 11C-RAC PET scans using a high-resolution condition are considered to provide essential information for regenerative dopaminergic therapy. Furthermore, the ratio analysis for the late-phase PET scans with 18F-FDOPA and 11C-RAC enhances the clinical utility of these dopaminergic PET as imaging biomarkers of PD.
Literature
1.
Sioka C, Fotopoulos A, Kyritsis AP. Recent advances in PET imaging for evaluation of Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2010;37:1594–603.CrossRefPubMed
2.
Hoffman JM, Melega WP, Hawk TC, Grafton SC, Luxen A, Mahoney DK, et al. The effects of carbidopa administration on 6-[18F]fluoro-l-dopa kinetics in positron emission tomography. J Nucl Med. 1992;33:1472–7.PubMed
3.
Ba F, Martin WRW. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord. 2015;21:87–94.CrossRefPubMed
4.
Morizane A, Doi D, Kikuchi T, Okita K, Hotta A, Kawasaki T, et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Rep. 2013;1:283–92.CrossRef
5.
Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59:459–66.CrossRefPubMed
6.
Oehme L, Perick M, Beuthien-Baumann B, Wolz M, Storch A, Löhle M, et al. Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with 18F-dopa brain PET in normal controls and patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2011;38:1550–9.CrossRefPubMed
7.
Frouin V, Comtat C, Reilhac A, Grégoire MC. Correction of partial-volume effect for PET striatal imaging: fast implementation and study of robustness. J Nucl Med. 2002;43:1715–26.PubMed
8.
Erlandsson K, Buvat I, Pretorius PH, Thomas BA, Hutton BF. A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Phys Med Biol. 2012;57:R119–59.CrossRefPubMed
9.
Bettinardi V, Presotto L, Rapisarda E, Picchio M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PET/CT Discovery-690. Med Phys. 2011;38:5394–411.CrossRefPubMed
10.
Pretze M, Wängler C, Wängler B. 6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses. Biomed Res Int. 2014;2014:674063.CrossRefPubMedPubMedCentral
11.
Shen B, Ehrlichmann W, Uebele M, Machulla H-J, Reischl G. Automated synthesis of n.c.a. [18F]FDOPA via nucleophilic aromatic substitution with [18F]fluoride. Appl Radiat Isot. 2009;67:1650–3.CrossRefPubMed
12.
Aita K, Ohnishi A, Akamatsu G, Sasaki M, Senda M. Synthesis of high specific activity [18F]FDOPA using a synthesizing device with a user-configurable cassette. J Nucl Med. 2016;57(suppl 2):1812.
13.
Jokinen P, Helenius H, Rauhala E, Brück A, Eskola O, Rinne JO. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med. 2009;50:893–9.CrossRefPubMed
14.
Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A, et al. Comparative analysis of striatal FDOPA uptake in Parkinson’s disease: ratio method versus graphical approach. J Nucl Med. 2002;43:1324–30.PubMed
15.
Pan X, Wright TG, Leong FJ, McLaughlin RA, Declerck JM, Silverman DHS. Improving influx constant and ratio estimation in FDOPA brain PET analysis for Parkinson’s disease. J Nucl Med. 2005;46:1737–44.PubMed
16.
Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab. 1996;16:42–52.CrossRefPubMed
17.
Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer D, MacGregor R, et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med. 1993;34:609–13.PubMed
18.
Brooks DJ, Ibanez V, Playford ED, Sawle GV, Leigh PN, Kocen RS, et al. Presynaptic and postsynaptic striatal dopaminergic function in neuroacanthocytosis: a positron emission tomographic study. Ann Neurol. 1991;30:166–71.CrossRefPubMed
19.
Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985;5:584–90.CrossRefPubMed
20.
Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153–8.CrossRefPubMed
21.
FDG-PET/CT Technical Committee. FDG-PET/CT UPICT, Quantitative Imaging Biomarkers Alliance. Version 1.0. Publicly Reviewed Version. QIBA, July 08, 2014. http://​RSNA.​org/​QIBA.
22.
Kuik W, Kema IP, Brouwers AH, Zijlma R, Neumann KD, Dierckx RAJO, et al. In vivo biodistribution of no-carrier-added 6-18F-fluoro-3,4-dihydroxy-l-phenylalanine (18F-DOPA), produced by a new nucleophilic substitution approach, compared with carrier-added 18F-DOPA, prepared by conventional electrophilic substitution. J Nucl Med. 2015;56:106–12.CrossRefPubMed
23.
Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, et al. Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol. 1992;31:184–92.CrossRefPubMed
24.
Lue KH, Lin HH, Kao CHK, Hsieh HJ, Liu SH, Chuang KS. A simple algorithm for subregional striatal uptake analysis with partial volume correction in dopaminergic PET imaging. Ann Nucl Med. 2014;28:33–41.CrossRefPubMed
25.
Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001;21:1034–57.CrossRefPubMed
26.
Hutchinson M, Raff U. Structural changes of the substantia nigra in Parkinson’s disease as revealed by MR imaging. AJNR Am J Neuroradiol. 2000;21:697–701.PubMed
27.
Kawaguchi H, Shimada H, Kodaka F, Suzuki M, Shinotoh H, Hirano S, et al. Principal component analysis of multimodal neuromelanin MRI and dopamine transporter PET data provides a specific metric for the nigral dopaminergic neuronal density. PLoS One. 2016;11:e0151191.CrossRefPubMedPubMedCentral
28.
Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, et al. Dopamine cell implantation in Parkinson’s disease: long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med. 2010;51:7–15.CrossRefPubMed
Metadata
Title
A revisit to quantitative PET with 18F-FDOPA of high specific activity using a high-resolution condition in view of application to regenerative therapy
Authors
Go Akamatsu
Akihito Ohnishi
Kazuki Aita
Hiroyuki Nishida
Yasuhiko Ikari
Masahiro Sasaki
Nobuo Kohara
Michio Senda
Publication date
01-02-2017
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 2/2017
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-016-1143-2

Other articles of this Issue 2/2017

Annals of Nuclear Medicine 2/2017 Go to the issue

Original Article

Improvement in automated quantitation of myocardial perfusion abnormality by using iterative reconstruction image in combination with resolution recovery, attenuation and scatter corrections for the detection of coronary artery disease

Original Article

Spatiotemporal distribution modeling of PET tracer uptake in solid tumors

Original Article

Coronary flow reserve and relative flow reserve measured by N-13 ammonia PET for characterization of coronary artery disease

Acknowledgements to Reviewers

Acknowledgements to reviewers

Original Article

Respiratory average CT for attenuation correction in myocardial perfusion SPECT/CT

Original Article

Effect of chemotherapy on the impact of FDG-PET/CT in selection of patients for surgical resection of colorectal liver metastases: single center analysis of PET-CAM randomized trial